The Avacta share price is up 1,750% in 1 year! Should I buy now?

The Avacta share price is surging! It’s up more than 1,750% in a year, but is it too late to buy the shares? Zaven Boyrazian investigates.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The Avacta Group (LSE:AVCT) share price has exploded over the past 12 months, increasing from 14p in March last year to over 260p today. That’s a surge of over 1,750%!

What caused this immense growth? And Should I be adding the stock to my portfolio? Let’s take a look.

Why did the Avacta share price explode last year?

Avacta is a small biotech company that focuses on the development and production of drugs and diagnostic medicines. While its expertise lies within cancer immunotherapeutics, in 2020, the firm began leveraging its knowledge to start designing a rapid Covid-19 test.

The company partnered with Cytiva to develop it back in April last year. And this project appears to be the primary catalyst behind Avacta’s surging share price. The upward momentum only continued as the company released a continuous stream of positive results and new partnerships to accelerate its test development.

In August, it was ready for clinical trials. In September, the manufacturing capacity was expanded. Later that month, a research kit became available for other pharmaceutical companies. More recently, in January this year, the preliminary results from early-stage trials showed a 96.7% accuracy in identifying Covid-19 infections within patients.

The company is now pursuing full clinical approval to launch its test within Europe before the end of Q1 2021. 100’s of millions of rapid Covid-19 tests will likely be needed throughout this year and beyond. Combining that with the additional royalties from treatments developed with its research kit, there is an enormous growth opportunity for Avacta and its share price.

Let’s take a step back

As promising as this company seems, the valuation is borderline insane. At least, I think so. Even if Avacta’s rapid Covid-19 test is approved and distributed throughout Europe, current forecasts indicate total revenue for 2021 of around £8m. And that’s including the income from its other product developments and collaborations unrelated to the pandemic.

Comparing that to the current market capitalisation of £689m places the price-to-sales ratio at 86. Needless to say, investor expectations may be a bit too high. And Avacta’s share price could come crashing right back down should its Covid-19 test fail to receive regulatory approval for use.

It’s true the preliminary results showed a 96.7% accuracy. But this was on a sample size of 30. A much larger number of patients needs to be tested before any approval can occur. And these new results could be vastly different.

The Avacta share price is quite risky

The bottom line

There is no denying that Avacta’s rapid Covid-19 test is an incredible opportunity for the business. If successful, the increased cash flow could lead to further development of its other offerings, generating even more growth over the long term.

However, business valuation matters. And personally, even if the most optimistic outcome were to occur, I believe Avacta’s share price is far too high. Therefore, I’m not adding the stock to my portfolio today.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Zaven Boyrazian does not own shares in Avacta Group. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Live: Coronavirus Market Crash Coverage

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

2 FTSE 250 stocks (including a 7.1% yield!) I’d love to buy in September!

The FTSE 250 is home to some of London's best value stocks to buy. Here are two I'll be looking…

Read more »

Investing Articles

Is a stock market crash coming? Here’s what I’m doing now!

UK share prices are collapsing again as concerns over the global economy rise. This is what I'll be doing if…

Read more »

Stack of British pound coins falling on list of share prices
Investing Articles

Is the ITM Power share price too cheap to miss?

The ITM Power share price has taken a battering as fears over its widening losses grow. Does this represent a…

Read more »

Investing Articles

2 of the best cheap FTSE 100 shares to buy for 2022!

I'm searching for the best FTSE 100 shares to load up on for the new year. I think these blue-chip…

Read more »

A couple hug having moved into their new home
Live: Coronavirus Market Crash Coverage

Revealed! How first-time buyers receive £30k towards buying a home

According to new research, first-time buyers are beating record house prices by accessing an average of £30k from a particular…

Read more »

Investing Articles

4 penny shares to buy if stock markets crash in December!

I'm searching for the best cheap UK shares as stock markets threaten to crash again. Here are four top penny…

Read more »

Investing Articles

A dirt-cheap FTSE 250 dividend stock I’d buy today

I'm hunting for the best income stocks to buy for my Stocks and Shares ISA. Here's a top-class FTSE 250…

Read more »

Investing Articles

A dirt-cheap UK growth share I’d buy for November!

Investor demand for this UK growth share has cooled in recent weeks. Here's why I think this could prove to…

Read more »